This is an extraordinary result Teclistamab (CD3 x BCMA bispecific antibody) plus Daratumumab (CD38 antibody) vs. standard care for relapsed or refractory multiple myeloma The future of medicine is very very bright

American Society of OncoNephrology Upcoming educational activity ✅Journal club: Bio-marker guided Influximab therapy @Arjun_Mohan1 @HerrmannMd @SabineKaram6 ✅December 12th, 12 PM EDT

Seeing the light (chains): a paradigm shift in PGNMID - Kidney International kidney-international.org/art… @JeanHouMD #renalpath #PGNMID

Dr Phil Halloran at CST on what the molecular microscope has taught us so far about kidney allograft rejection - “rejection is a chronic condition not an episode”.

CAR-T therapy and Lymph node architecture Amazing lecture by @BradRovin on Lupus Nephritis #GlomConHawaii

We are honored to welcome 🤗 Dr Pierre Ronco as Visiting Professor at @MayoClinicNeph #MedEd Grand Rounds tilted “New advances in immune-mediated podocytopathies: Is anti-nephrin the new anti-PLA2R?” 👩‍🔬 Key Conclusions •🧪 Anti-nephrin antibodies confirmed as correlating with disease activity and likely involved in GCW alterations •🧭 First biomarker available for diagnosis/monitoring in children + adults; may help prevent post-transplant relapses •🧫 ELISA assays for clinical use coming soon (Euroimmun, bridge ELISA for research) •🧩 New concept: Slit diaphragm antigens (nephrin, podocin, NEPH1, NEPH3) drive autoimmune podocytopathies ❓ Key Open Questions •🔮 Can anti-nephrin antibodies predict steroid dependence/resistance? •📈 Is there correlation between antibody levels and outcomes? •🔁 Can they predict relapse? •🧬 What are the antigenic targets in anti-nephrin negative patients (esp. primary FSGS)? •⚠️ Are all anti-nephrin antibodies pathogenic? •🧠 Other permeability factors yet to be found? •⏱ Why is remission so fast after steroids? •🧾 What is the mechanism of immunization? •🕰 Perspective: “18 years after anti-PLA2R discovery, we still do not know everything!”

🚨 Editor’s Choice 🚨 "The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study," by Wellekens et al. amjtransplant.org/article/S1…

I really enjoyed this year’s ASON symposium. Learned lots, reconnected with friends and mentors, and made new friends. Grateful to @HerrmannMd, Dr Nelson Leung, and @LeticiaRolonMD for the invitation. Looking forward to next year’s symposium already! 🥂

Final picture! We would like to thank all the Speakers and Moderators and everyone who attended in person and livestream ! Safe travels back home . @rc_oncneph @LeticiaRolonMD @onconeph @AbdullahJalalMD @MayoClinicNeph @onconephsociety

👀 Check out our September Literature Watch, "Location, location, location—How real estate immunity and preservation of self are defined" by Drinkwater et al: amjtransplant.org/article/S1…

Membranous nephropathy has undergone a paradigm shift due to the discovery of unique MN antigens. MN has gone from idiopathic to ➡️ primary vs. secondary ➡️ where an antigen can be detected in ~80% of MN. This is a comprehensive review of each antigen. nature.com/articles/s41581-0…

1/5 SPLENOMEGALY/HYPERSPLENISM Mechanisms of splenomegaly: • Congestive • Work hypertrophy • Infiltrative What enlarges? • Red pulp: macrophages, sinusoids, blood • White pulp: lymphocytes, plasma cells • Infiltrative: tumor, storage cells, granulomas, amyloid #MedEd

Important new arguments for the discussion, which B cell-targeting therapy to involve in the treatment of autoimmune diseases. May be even more important in alloimmunity? ard.eular.org/article/S0003-…

Not all drug related TMA’s are made equal. But for a subset (I.e. VEGFi, Gemcitabine), terminal complement blockade allows continuation of the offending drug, with important implications for progression free survival in the long term.

Excited to share our experience using complement inhibition for re-challenging and maintaining anti-VEGF therapy in renal limited TMA. A valuable strategy to keep patients on life-saving treatment #onconephrology @HerrmannMd @delphile @KIReports @onconephsociety @MayoClinicNeph ➡️kireports.org/article/S2468-…

Baffling: PGNMID, monoclonal no more I got this consult case as immune complex-MPGN LM- MPGN pattern IF- IgG, C3, C1q, kappa & lambda 3+ Did IgG subtypes-IgG3 3+, all others negative EM- mottled deposits Dx- Proliferative GN, IgG3, but ? with monoclonal IgG deposits (PGNMID)

Don't miss this @MayoClinicNeph conference! Onco-Nephrology Symposium will cover nephrotoxicity of chemotherapeutic agents, patients with dialysis-dependent end-stage renal disease, & much more. Register for Sept. 11-12 in Minnesota & via livestream. ce.mayo.edu/nephrology/conte…

IgM Variant of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits: A Case Series bit.ly/3Ec18Od #OpenAccess @Bhanu2405 @SethiRenalPath #VisualAbstract

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/45mitxx

💡New resources- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia. Useful info on pre-tx eval, post-tx monitoring of recurrence, immunosuppression mgmt. @Kidney_Int @AST_KPCOP w IKMG. More info 👇. kidney-international.org/art…